The Role of ErbB Inhibitors in Trastuzumab Resistance

The Role of ErbB Inhibitors in Trastuzumab Resistance Kathy D. Miller Oncologist 2004; 9 (Suppl 3): 16-19 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss mechanisms of resistance to EGFR inhibitor monotherapy. Cite potential treatment strategies and ongoing clinical trials to prevent or delay the development of resistance to EGFR inhibitors. Describe results of clinical trials using EGFR inhibitors in patients with metastatic breast cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 26, 2004 Most Recent Review: May 26, 2004* Most Recent Update: May 26, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of The Future of ErbB-1 and ErbB-2 Pathway Inhibition in Breast Cancer: Targeting Multiple Receptors.